The report Titled “Brazil Pharmaceuticals Market Outlook to 2025 – By International and Domestic Companies, By Retail and Institutional Sales, By Institutional Sales (Public, Private and Others), By Drug Type (Prescription, Over-The-Counter and Generics), By Generic Drug Type (Branded and Local), By Region (Southeast, South, Northeast, Midwest and North), By Therapeutic Areas” by Ken Research suggested that the Brazil Pharmaceuticals Market has been increasing due to the increasing per capita health expenditure, growing number of Chronic diseases, increasing demand of generic drugs in the market coupled with new market opportunities for Domestic Manufacturers.
Growing Government Initiatives: Government in Brazil promoted initiatives such as the Growth Acceleration Program and the Greater Brazil Plan that were introduced largely to increase domestic production of drugs in Brazil. Growth Acceleration Program is focused on modernizing public infrastructure, while the Greater Brazil Plan encourages local production of innovative drugs and also promoting public – private partnerships in the form of technology transfer to other pharmaceutical laboratories for the development of higher-priced biosimilar drugs.
Growing Number of Substitutes for Patented Drugs: Generic Drugs alternatives are available for 95% of the treatments in Brazil. The local manufacturing companies on the other hand are largely involved in the manufacturing activities of the generic drugs and are now focusing on increasing their production targets of generics in different therapeutic areas so as to compete with patented drugs manufacturers in Brazil. Generic Drugs in the country are also becoming increasingly popular with prescription or in Over-The-Counter form, as consumers perception towards generic drugs to be taken as equivalent to the branded medications is also growing.
Growing Number of Mergers and Acquisitions: Growing ageing population of Brazil and increase in demand for generic and other medicines has led major players in the industry to expand in terms of their production capabilities. So as to capture the potential areas, the industry has witnessed various mergers and acquisitions over the last few years. The companies have majorly focused on acquiring smaller companies or brands in order to expand their product portfolio or add a new business segment.
The market is expected to register a positive CAGR of 8.4% in terms of revenue during the forecast period 2018-2025.
Key Segments Covered
By Type of Companies
International Companies
Domestic Companies
By Type of Channel
Institutional
Public
Private
Others
Retail
By Drug Type
Prescription
Over-The-Counter
Generics
Branded
Local
By Region
Southeast
South
Midwest
Northeast
North
By Therapeutic Areas
Cardiovascular
Central Nervous System
Respiratory
Oncology
Anti-Infective
Gastrointestinal
Others
Key Target Audience
Pharmaceutical Manufacturing Companies
Pharmacy Retail Outlets
Government/ Regulatory Authorities
Venture Capitalist Firms
Health Insurance Companies
Pharmaceutical Products Distributors
Time Period Captured in the Report:
Historical Period: 2013-2018
Forecast Period: 2019F-2025F
Companies Covered:
Major Manufacturers
Ache Laboratories
EMS Pharma
Eurofarma
Sanofi
Novartis
Neo Quimica
Mantecopr Farmasa
Libbs
Biolab- Sanus Farma
Takeda Pharma
Medley
Bayer Pharma
CIMED
Pfizer
GSK Pharma
FQM Grupo
Hypera Ch
Abbott Laboratories
Janssen Pharmaceuticals
Key Topics Covered in the Report
Brazil Pharmaceuticals Market Overview and Genesis (Overview and Genesis, Business Cycle Graph)
Brazil Pharmaceutical Market Value Chain Analysis
Brazil Pharmaceutical Market Size
Brazil Pharmaceuticals Market Segmentation
Regulatory Landscape in Brazil Pharmaceuticals Market
Trends and Developments in Brazil Pharmaceuticals Market
Issues and Challenges in Brazil Pharmaceuticals Market
Brazil Pharmaceuticals Market Competition Landscape
Cross Comparison of 7 Major Players in Brazil Pharmaceuticals Market
Brazil Pharmaceuticals Market Future Projection, 2018-2025F
Future Outlook of Brazil Pharmaceuticals Market Segmentations, 2018-2025F
Analyst Recommendations
For more information, refer to below link:
Related Reports
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
